Literature DB >> 615720

Renal clearance of pyridostigmine in patients with myasthenia gravis.

K Chan, T N Calvey.   

Abstract

The urinary clearance of pyridostigmine was studied in six patients with myasthenia gravis. In three patients on pyridostigmine alone, renal clearance ranged from 349 to 481 ml/min, corresponding to a pyridostigmine:creatinine clearance ratio of 2.64 to 3.46. In a patient on bendrofluazide as well as pyridostigmine, a similar clearance ratio was observed. By contrast, the urinary clearance of pyridostigmine and the pyridostigmine:creatinine clearance ratio was reduced in two myasthenic patients concurrently treated with other basic drugs. It is suggested that these results may reflect competition for renal tubular excretion.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 615720     DOI: 10.1159/000114882

Source DB:  PubMed          Journal:  Eur Neurol        ISSN: 0014-3022            Impact factor:   1.710


  5 in total

Review 1.  Clinical pharmacokinetics of cholinesterase inhibitors.

Authors:  S M Aquilonius; P Hartvig
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

2.  Clinical pharmacology of pyridostigmine and neostigmine in patients with myasthenia gravis.

Authors:  S M Aquilonius; S A Eckernäs; P Hartvig; B Lindström; P O Osterman; E Stålberg
Journal:  J Neurol Neurosurg Psychiatry       Date:  1983-10       Impact factor: 10.154

3.  Controversies about the treatment of myasthenia gravis.

Authors:  L P Rowland
Journal:  J Neurol Neurosurg Psychiatry       Date:  1980-07       Impact factor: 10.154

4.  Pyridostigmine in human breast milk.

Authors:  L I Hardell; B Lindström; G Lönnerholm; P O Osterman
Journal:  Br J Clin Pharmacol       Date:  1982-10       Impact factor: 4.335

5.  Pharmacokinetics and oral bioavailability of pyridostigmine in man.

Authors:  S M Aquilonius; S A Eckernäs; P Hartvig; B Lindström; P O Osterman
Journal:  Eur J Clin Pharmacol       Date:  1980-11       Impact factor: 2.953

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.